VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
Amgen Inc. vs Brookfield Infrastructure Partners L.P.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Amgen Inc.
AMGN · Nasdaq Stock Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Brookfield Infrastructure Partners L.P.
BIP · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Brookfield Infrastructure Partners L.P.'s moat claims, evidence, and risks.
View BIP analysisComparison highlights
- Moat score gap: Brookfield Infrastructure Partners L.P. leads (74 / 100 vs 70 / 100 for Amgen Inc.).
- Segment focus: Amgen Inc. has 3 segments (80.1% in Core Innovative Medicines); Brookfield Infrastructure Partners L.P. has 4 segments.
- Primary market structure: Competitive vs Quasi-Monopoly. Pricing power: Moderate vs Moderate.
- Moat breadth: Amgen Inc. has 5 moat types across 3 domains; Brookfield Infrastructure Partners L.P. has 4 across 3.
Primary market context
Amgen Inc.
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Global
Payers, providers, and pharmacies
Drug developer/manufacturer
80.1%
Brookfield Infrastructure Partners L.P.
Utilities
Regulated and contracted utility infrastructure (electric transmission, gas pipelines/distribution, metering and residential energy services)
Global
Regulators and contracted counterparties; residential and commercial end-users via utility networks
Owner-operator of regulated networks and contracted utility assets
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Amgen Inc. strengths
Brookfield Infrastructure Partners L.P. strengths
Segment mix
Amgen Inc. segments
Full profile >Core Innovative Medicines
Competitive
Rare Disease Portfolio (Horizon + others)
Quasi-Monopoly
Biosimilars
Oligopoly
Brookfield Infrastructure Partners L.P. segments
Full profile >Utilities
Quasi-Monopoly
Transport
Oligopoly
Midstream
Oligopoly
Data
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.